We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

157 hedge funds and large institutions have $1.59B invested in Arcus Biosciences in 2022 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 44 increasing their positions, 55 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more call options, than puts

Call options by funds: $23.4M | Put options by funds: $11.1M

79% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 19

33% more funds holding in top 10

Funds holding in top 10: 6 → 8 (+2)

11% more funds holding

Funds holding: 142 → 157 (+15)

1.11% less ownership

Funds ownership: 72.35% → 71.25% (-1.1%)

20% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 55

23% less capital invested

Capital invested by funds: $2.06B → $1.59B (-$468M)

Holders
157
Holders Change
+15
Holders Change %
+10.56%
% of All Funds
2.48%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.13%
New
34
Increased
44
Reduced
55
Closed
19
Calls
$23.4M
Puts
$11.1M
Net Calls
+$12.3M
Net Calls Change
+$15.5M

Top Buyers

1
AllianceBernstein
AllianceBernstein
Tennessee
+$34.4M
2
APM
Avidity Partners Management
Texas
+$30.6M
3
BI
BVF Inc
California
+$18.9M
4
State Street
State Street
Massachusetts
+$18.7M
5
PA
Perceptive Advisors
New York
+$13.6M

Top Sellers

1
EC
EcoR1 Capital
California
-$75.7M
2
WP
Woodline Partners
California
-$48.4M
3
Morgan Stanley
Morgan Stanley
New York
-$39.7M
4
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$15M
5
Franklin Resources
Franklin Resources
California
-$14.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$131M +$322K +9,597 +0.2%
BI
2
BVF Inc
California
$125M +$18.9M +562,881 +17%
Vanguard Group
3
Vanguard Group
Pennsylvania
$111M +$2.87M +85,778 +3%
PHS
4
PFM Health Sciences
California
$108M – – –
Fidelity Investments
5
Fidelity Investments
Massachusetts
$105M +$4.26M +127,118 +4%
EC
6
EcoR1 Capital
California
$103M -$75.7M -2,258,257 -41%
State Street
7
State Street
Massachusetts
$86.8M +$18.7M +557,988 +25%
AI
8
Alphabet Inc
California
$80.9M – – –
OCA
9
Octagon Capital Advisors
New York
$78.6M +$13.2M +394,743 +19%
IFA
10
Invus Financial Advisors
New York
$50.9M – – –
PAMS
11
Pictet Asset Management (Switzerland)
Switzerland
$49.1M -$3.15M -93,978 -6%
BC
12
Boxer Capital
California
$45.2M – – –
AllianceBernstein
13
AllianceBernstein
Tennessee
$33.8M +$34.4M +1,025,643 +2,315%
APM
14
Avidity Partners Management
Texas
$28.8M +$30.6M +912,000 New
DCMIC
15
Decheng Capital Management III (Cayman)
Cayman Islands
$27.5M +$29.1M +869,790 New
TCM
16
TimesSquare Capital Management
New York
$25.9M -$4.78M -142,770 -15%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$25.2M +$939K +28,030 +4%
BNP Paribas Asset Management
18
BNP Paribas Asset Management
France
$25.2M -$2.15M -64,203 -7%
Franklin Resources
19
Franklin Resources
California
$23.9M -$14.3M -427,766 -36%
Northern Trust
20
Northern Trust
Illinois
$18.9M -$800K -23,862 -4%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$13.8M +$6.38M +190,527 +77%
JP Morgan Chase
22
JP Morgan Chase
New York
$13.8M +$5.61M +167,381 +62%
PA
23
Perceptive Advisors
New York
$12.8M +$13.6M +405,000 New
SAM
24
Sectoral Asset Management
Quebec, Canada
$10.7M +$1.85M +55,270 +20%
Charles Schwab
25
Charles Schwab
California
$10.4M +$285K +8,501 +3%
1
2 3 4 5

RCUS Hedge Fund Activity: Q1 2022 in Review

157 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2022, worth a combined $1.59B — down 23% from $2.06B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new RCUS positions and 19 closed out — a net gain of 15 holders — while 44 added to existing stakes and 55 trimmed.

The largest buyer was AllianceBernstein, adding an estimated $34.4M. The largest seller was EcoR1 Capital, cutting an estimated $75.7M.

  • 157 institutional investors held Arcus Biosciences (RCUS) as of Q1 2022, up from 142 in Q4 2021.
  • Funds reported $1.59B of Arcus Biosciences stock for Q1 2022, down 23% quarter-over-quarter.
  • 34 funds opened new Arcus Biosciences positions in Q1 2022 and 19 closed out, a net change of +15 holders.
  • The largest Arcus Biosciences buyer in Q1 2022 was AllianceBernstein, an estimated $34.4M added.
  • The largest Arcus Biosciences seller in Q1 2022 was EcoR1 Capital, an estimated $75.7M sold.

Based on aggregated 13F filings for Q1 2022.